Details of the Drug
General Information of Drug (ID: DMDOX1Z)
Drug Name |
Etoloxamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Etoloxamine; UNII-NEZ417265P; CHEMBL366265; 1157-87-5; NEZ417265P; Etoloxaminum; Etoloxamina; Aetholoxaminum; etoloxamine[inn]; Etoloxamine [INN]; Etoloxaminum [INN-Latin]; Etoloxamina [INN-Spanish]; 2-(2-benzylphenoxy)-N,N-diethylethanamine; AC1L2ASA; AC1Q57OP; SCHEMBL2110223; ZINC1407; BPXIOWINQPQVOY-UHFFFAOYSA-N; BDBM50151052; 2-((alpha-Phenyl-o-tolyl)oxy)triethylamine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 283.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||||||||